Aim: Flare-ups of chronic hepatitis B can sometimes be severe and even progress to acute-on-chronic liver failure (ACLF), with high short-term mortality. A timely estimation of the risk of death should be initiated early. The aim of the present study was to determine whether novel biomarkers add prognostic information beyond current clinical scoring systems.
INTRODUCTION
C HRONIC HEPATITIS B (CHB) remains a major health problem worldwide. 1 Acute exacerbation of CHB frequently occurs during its natural history. 2 In certain cases, CHB patients could suffer from severe flareups and are at substantial risk of developing acute-onchronic liver failure (ACLF). [3] [4] [5] [6] A recent study reported that ACLF patients have excellent outcomes after liver transplantation (LT) but high mortality while on the waiting list, 7 implying a narrow "golden window" in which prompt interventions significantly improve the outcome. Therefore, a rapid accurate evaluation of risk of death is especially critical for management of ACLF patients. However, it remains difficult, despite the availability of various scoring systems such as the Model for End-stage Liver Disease (MELD), Asian-Pacific Association for the Study of the Liver (APASL)-ACLF Research Consortium score (AARC-ACLF score), and the Chronic Liver Failure (CLIF) Consortium ACLF score (CLIF-C ACLFs). 8, 9 We postulated that a panel of novel biomarkers would provide additional prognostic information and add to existing riskprediction algorithms established by generally available clinical and biochemical parameters.
In recent years, several biomarkers have been explored in prognostication of liver diseases. Cluster of differentiation (CD) 163 is a hemoglobin-haptoglobin scavenger receptor mainly expressed on monocytes/macrophages. CD163 has a pivotal role in host defense and resolution of inflammation. 10 The soluble form of CD163 (sCD163) is generated by ectodomain shedding triggered by an inflammatory stimulus and is released to circulatory compartment. Recent studies have shown that circulating sCD163 predicts mortality of patients with end-stage liver diseases or acute liver failure. 11, 12 Neutrophil gelatinase-associated lipocalin (NGAL) was first identified from human stimulated neutrophils as a gelatinase-associated protein and can be detectable in various fluid and tissue extracts. 13 Neutrophil gelatinase-associated lipocalin is an acute-phase protein and modulates various immune responses, especially the antibacterial response. 13 Urine and plasma NGAL have been shown to be biomarkers for acute kidney injury in patients with decompensated cirrhosis, especially those with bacterial infections, and to predict mortality. 14, 15 Copeptin is the precursor of arginine vasopressin, which modulates the hemodynamic homeostasis. 16 Copeptin has been shown to be associated with circulatory and renal dysfunction in de-compensated cirrhosis. 17 However, these potential biomarkers have not been tested in critically ill hepatitis B patients. Therefore, in the present study, we investigated the individual and collective utility of plasma sCD163, NGAL, and copeptin for predicting outcomes in hepatitis B-precipitated (HB)-ACLF patients. Patients were excluded from the study if they: (i) were <18 years or >70 years of age; (ii) had confirmed or suspected malignancy; (iii) were pregnant; (iv) had undergone previous organ transplantation; or (v) had severe extrahepatic diseases.
METHODS
Diagnosis of ACLF was by APASL-ACLF consensus. 18 Acute-on-chronic liver failure was further categorized as early (no organ failure), moderate (failure of one organ), and advanced (failure of two or more organs). Organ failures of liver, coagulation, kidney, circulation, lung, or cerebral systems were defined by the CLIF-SOFA score. 19 All the patients were hepatitis B surface antigen (HBsAg)-positive for at least 6 months qualitative detection of HBsAg S/ CO≥1 or quantification of HBsAg>0.05 IU/ml. Flare-up of hepatitis B was defined as a rise of alanine aminotransferase (ALT) >5 times the normal upper limit or more than twice the baseline value with replicating hepatitis B virus DNA within 3 months before admission.
This study was in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of each participating hospital. Written consent was obtained from each participant or their legal representatives.
Data collection, end-point, and follow-up
The following clinical and demographic information was collected in a prespecified datasheet: age, sex, etiology and severity of chronic liver diseases, etiology of acute liver injury, and laboratory parameters. The study end-point was 28-day mortality. For discharged patients, prognostic information was verified by medical records, telephone contact, or visits.
Calculation of clinical scoring models
The MELD score is calculated as: 9. The CLIF-C ACLFs is calculated as: 10 × (0.33 × chronic liver failure-organ failures + 0.04 × age + 0.63 × Ln [white blood cell count] -2). 22 The AARC-ACLF score is the sum of five parameters: hepatic encephalopathy, lactate, creatinine, bilirubin, and INR. centrifuged at 400 g for 10 min at 4°C and the supernatant stored at À80°C until analysis. The concentrations of plasma sCD163, NGAL, and copeptin were measured by enzyme-linked immunosorbent assays (ELISA) in a central laboratory using a human sCD163 ELISA kit purchased from R&D Systems (Minneapolis, MN, USA), a human NGAL ELISA kit purchased from BioLegend (San Diago, CA, USA), and a human copeptin ELISA kit purchased from Arigo (Hsinchu city, Taiwai, China). The detection thresholds are 0.18 ng/mL for sCD163, 16.4 pg/mL for NGAL, and 0.12 ng/mL for copeptin. The intra-assay coefficients of variation (CV) for measuring sCD163, NGAL, and copeptin are 3.4-3.8%, 5.8-7.4%, and <10%, respectively. The inter-assay CV for measuring sCD163, NGAL, and copeptin are 4.1-4.6%, 7.0-7.6%, and <15%, respectively.
Statistical analysis
Variables were compared using Student's t-test, the MannWhitney U-test, or the χ 2 -test. Kaplan-Meier survival curves were drawn and compared using the log-rank test. The cut-off value of plasma biomarkers for categorizing was adopted as median. A proportional hazards (Cox) model was used to explore the association between biomarkers and risk of death, including individual biomarkers or a combination of them, with or without accounting for available prognostic scores. Patients with LT or loss of follow-up were analyzed as censored at the date of transplantation or discharge.
New scores were developed by combining multiple biomarkers and available scoring models as follows: (regression coefficients β1) × (biomarker 1) + (regression coefficients β2) × (biomarker 2) + (regression coefficients β3) × (biomarker 3) + (regression coefficients β4) × (clinical prognostic scores). Regression coefficients denote proportional hazards regression coefficients for variables from multivariable Cox proportional hazards models.
The performance of scoring models with or without biomarkers was compared with an emphasis on discrimination and calibration. Censored data due to loss of follow-up or LT were excluded. The calibration of models was evaluated by the Akaike information criteria (AIC). The discrimination of models was measured by the area under the receiving operator characteristic curve (AUROC), integrated discrimination improvement (IDI), and the net reclassification improvement (NRI) metric. The NRI evaluates the proportion of patients whose risk was correctly reclassified by incorporating biomarkers into clinical score models. All the statistical analysis was undertaken with R software (version 3.1.2; The R Foundation for Statistical Computing, http://www.r-project.org/) and differences were considered significant at P < 0.05.
RESULTS

Characteristics of patients
A TOTAL OF 151 HB-ACLF patients were enrolled in the present study. As shown in Table 1 , the studied patients had a mean age of 49 ± 13 years, with a predominance of men (126/151, 83.4%). Co-existence of 
Plasma levels of biomarkers in HB-ACLF
We first tested whether the concentrations of plasma biomarkers (sCD163, NGAL, and copeptin) correlated with disease severity in HB-ACLF patients. Overall, as shown in Figure 1 , advanced ACLF patients had significantly higher levels than early ACLF individuals of plasma biomarkers sCD163 (P = 0.001), NGAL (P = 0.006), and copeptin (P = 0.049). However, a stepwise elevation with disease severity was not found. We next examined whether plasma levels of biomarkers in HB-ACLF were confounded by the presence of bacterial infections or high alcohol consumption. There was no significant difference in concentrations of plasma biomarkers between patients with or without bacterial infections. Patients with HB-ACLF complicated by high alcohol consumption had significantly lower levels than those exclusively precipitated by hepatitis B of plasma biomarker copeptin (P = 0.0087), but not sCD163 (P = 0.19) or NGAL (P = 0.57) (Figure 1 ). We also investigated the differential levels of these biomarkers according to factors related to ACLF (Table S1 ). Patients with overt ascites had significantly higher levels of sCD163 (P = 0.021) and copeptin (P = 0.035) than those without. Patients with severe jaundice had significantly higher levels of NGAL (P = 0.003) and copeptin (P = 0.0004) than those without. Patients with coagulation failure had significantly higher level of sCD163 (P = 0.003) and NGAL (P = 0.002) than those without.
Association between biomarkers and 28-day mortality
We then examined whether plasma biomarkers sCD163, NGAL, and copeptin were associated with mortality. As shown in Figure 2 , patients with high levels of plasma sCD163 (P = 0.014) and NGAL (P < 0.001), but not copeptin (P = 0.093), had poorer short-term outcomes than those with low levels of biomarkers. Adjusting for MELD, AARC-ACLFs, and CLIF-C ACLFs, plasma sCD163 and NGAL showed a strong association with 28-day mortality, with a 2-4-fold increase in risk estimated by analysis for individual biomarkers or combined biomarkers, whereas plasma copeptin showed no significant association with mortality by adjusting for clinical scoring models ( Table 2 ). The association between plasma sCD163 and NGAL and 28-day mortality was independent of other demographic and clinical variables (Table S2 ).
Development of multibiomarker-incorporating scores
We next constructed new scores by incorporating sCD163 and NGAL into MELD, AARC-ACLFs, and CLIF-C ACLFs, assuming novel biomarkers provide additional prognostic information. As described in "Methods", a Bio-MELD score was calculated as:
A Bio-AARC-ACLFs was calculated as:
A Bio-CLIF-C ACLFs was calculated as:
Finally, we compared the predictive ability of scoring systems with or without biomarker incorporation. As shown in Table 3 , the addition of multiple biomarkers improved the calibration of MELD, AARC-ACLFs, and CLIF-C ACLFs, which was shown by a decrease of AIC. The sensitivity of discrimination increased by 9.2% in MELD (P = 0.012), 17% in MELD (P < 0.001), and 12% in MELD (P < 0.001). Bio-MELD and Bio-AARC-ACLFs conferred a high AUROC of 0.91 and 0.85, respectively, significantly higher than that of MELD (0.81) and AARC-ACLFs (0.79). There was no significant increase of AUROC when comparing Bio-CLIF-C ACLFs and CLIF-C ACLFs (0.85 vs. 0.85, P = 0.98).
Addition of biomarkers significantly enhanced the risk stratification ability of scoring models. As measured by NRI, addition of biomarkers into MELD, AARC-ACLFs, and CLIF-C ACLFs correctly reclassified 33.1%, 33.3%, and 21.2% of patients, respectively, according to risk of death (see Table 4 ).
DISCUSSION
O UR PRESENT STUDY revealed that novel biomarkers plasma sCD163 and NGAL are independent prognostic factors for short-term mortality in patients with HB-ACLF, which shed new light on the pathogenesis of the disease. Furthermore, use of a combination of these two biomarkers improves the predictive value of clinical scoring models.
Relevance with pathogenesis of ACLF
The hemoglobin-haptoglobin scavenger receptor CD163 is mainly expressed on the surface of macrophages and is released to the circulatory system in soluble form after Figure 2 Kaplan-Meier survival curves of patients with hepatitis B-related acute-on-chronic liver failure with high or low levels of individual biomarkers. Cut-off values of plasma soluble CD163 (sCD163), neutrophil gelatinase-associated lipocalin (NGAL), and copeptin were 295.4 ng/mL, 1998 pg/mL, and 0.75 ng/mL, respectively.
shedding. 10 Circulating sCD163 has been used as a surrogate marker for macrophage activation and correlates with liver disease severity. 12, 23, 24 Our study supported this, as it showed a significantly higher level of plasma sCD163 in deceased patients compared to survivors. The Kupffer cell activation in ACLF precipitated by acute hepatic injury can be strengthened by a large release of damageassociated molecular patterns (DAMPs) from sub-massive necrosis of hepatocytes, or by translocation of intestinal microbiota or their pathogen-associated molecular patterns. 25 Such profound activation of Kupffer cells could lead to systemic inflammation by secreting a milieu of pro-inflammatory cytokines or passively released DAMPs following necroptosis into circulation. 26 Neutrophil gelatinase-associated lipocalin is the product of the lipocalin-2 gene (LCN2) that is extensively expressed in a number of tissues and cell types, particularly neutrophils. 15 Urine and plasma NGAL have been reported as biomarkers for acute kidney injury in patients with decompensated cirrhosis and to predict mortality. 27 However, a recent study showed that the association between NGAL and mortality in decompensated cirrhosis is independent of renal function. 28 In addition, hepatic expression of LCN2 is significantly upregulated in ACLF and correlated with INR and bilirubin, suggesting liver injury as another source of urine and plasma NGAL. 15 It was also confirmed in an experimental model of partially hepatectomy. 29 To support it, in our study, the association between plasma NGAL and mortality independent of creatinine was revealed in patients, exclusively precipitated by liver injury. It should be noted that an extremely low incidence of acute kidney injury or renal failure occurred in these patients in which plasma NGAL was measured. In addition, our previous study showed that neutrophils are markedly activated in HB-ACLF, 30 with upregulation of antibacterial gene expression. Neutrophils are a major cell type expressing LCN2 that are actively involved in combat with bacterial infections, 31 and might also contribute to increased plasma NGAL. Collectively, increased plasma NGAL in ACLF precipitated by hepatitis B seems to be attributable to severe liver injury and neutrophil activation.
Copeptin is a 39 amino acid-long peptide derived from the precursor of arginine vasopressin, which is involved in multiple cardiovascular and renal pathways. 17 Copeptin was recently reported to be associated with hemodynamic dysfunction and mortality in decompensated cirrhosis. 17 However, in our study, no obvious association with mortality was found. In line with these results, renal or circulation dysfunction or failure was rarely observed in our patients at baseline, suggesting a lack of hemodynamic dysfunction in the pathogenesis of hepatitis B-induced ACLF at early stages. 2 
Translational significance
Liver transplantation remains to be the only effective therapy for patients who have poor response to conventional medical treatment. An accurate decision whether to perform LT is critically important. Patients with underestimated risk would delay LT, which would substantially increase mortality. Patients with overestimated mortality risk would inappropriately receive LT, which would be a heavy burden both to individuals and public health due to high medical costs and organ shortages. Therefore, an optimal prognostic model would both differentiate those at higher risk of death from those at lower risk well, which is defined as discrimination, and predict absolute risk close to the true risk, which is defined as calibration. By measuring AUROC, IDI, and AIC, we showed that the addition of sCD163 and NGAL significantly improved discrimination and calibration of available clinical scoring models. The reclassification analysis further informs the value of biomarker testing. Addition of biomarkers into clinical scoring models correctly reclassified 21-33% of patients according to risk of death. More importantly, the accuracy of risk estimation was improved in both death and survivor groups. This finding establishes the merit of biomarker test in reducing the error of underestimating and overestimating mortality risk simutaneously. Although the sample size in the study was not large, the incidence of end-point events was high due to high mortality, allowing statistical analysis for prognosis prediction. Furthermore, our patients were enrolled from multiple centers, making the results robust for extrapolation. However, it remains to be validated whether the conclusion is applicable in severe alcoholic hepatitis, which predominates in the etiologies of ACLF in many countries and areas, such as Europe 32 and North America. 33 Collectively, our findings revealed that sCD163 and NGAL are useful biomarkers in patients with HB-ACLF, highlighting them as an inflammation-driving disease.
